⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for veliparib

Every month we try and update this database with for veliparib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung CancerNCT01642251
Extensive Stage...
Large Cell Lung...
Neuroendocrine ...
Small Cell Carc...
Stage IV Non-Sm...
Cisplatin
Etoposide
Veliparib
Placebo
18 Years - National Cancer Institute (NCI)
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeNCT00770471
Brain and Centr...
temozolomide
veliparib
DNA methylation...
gene expression...
mutation analys...
proteomic profi...
high performanc...
immunoenzyme te...
laboratory biom...
mass spectromet...
pharmacogenomic...
pharmacological...
adjuvant therap...
radiation thera...
18 Years - 120 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid TumorsNCT01154426
Adult Solid Neo...
BRCA1 Mutation ...
BRCA2 Mutation ...
Diagnostic Labo...
Gemcitabine Hyd...
Pharmacological...
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast CancerNCT01477489
Breast Cancer
Veliparib
Standard radiat...
19 Years - University of Michigan Rogel Cancer Center
To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid TumorsNCT01199224
Solid Tumors
veliparib
veliparib
veliparib
veliparib
18 Years - AbbVie
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionNCT01366144
Breast Carcinom...
Carcinoma of Un...
Endometrial Car...
Esophageal Carc...
Liver Failure
Lung Carcinoma
Malignant Head ...
Malignant Testi...
Melanoma
Metastatic Mali...
Ovarian Carcino...
Renal Failure
Unresectable Ma...
Urothelial Carc...
Carboplatin
Laboratory Biom...
Paclitaxel
Pharmacological...
Veliparib
18 Years - National Cancer Institute (NCI)
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate CancerNCT01576172
Castration-Resi...
Recurrent Prost...
Stage IV Prosta...
Abiraterone Ace...
Laboratory Biom...
Prednisone
Veliparib
18 Years - National Cancer Institute (NCI)
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerNCT00989651
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Brenner...
Ovarian Carcino...
Ovarian Carcino...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Primary Periton...
Stage IIA Fallo...
Stage IIA Ovari...
Stage IIB Fallo...
Stage IIB Ovari...
Stage IIC Fallo...
Stage IIC Ovari...
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Bevacizumab
Carboplatin
Cisplatin
Laboratory Biom...
Paclitaxel
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid TumorsNCT01017640
Solid Neoplasm
Laboratory Biom...
Mitomycin
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA StatusNCT01690598
Ovarian Cancer
Veliparib
Topotecan
18 Years - Vejle Hospital
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid TumorsNCT01233505
Adenocarcinoma ...
Adenocarcinoma ...
BRCA1 Mutation ...
BRCA2 Mutation ...
Ovarian Mucinou...
Recurrent Breas...
Recurrent Colon...
Recurrent Gastr...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Pancr...
Recurrent Recta...
Stage IA Breast...
Stage IB Breast...
Stage II Breast...
Stage IIIA Brea...
Stage IIIB Brea...
Stage IIIC Brea...
Stage IV Breast...
Stage IV Colon ...
Stage IV Gastri...
Stage IV Ovaria...
Stage IV Ovaria...
Stage IV Pancre...
Stage IV Rectal...
Unspecified Adu...
veliparib
capecitabine
oxaliplatin
pharmacological...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung CancerNCT01657799
Brain Metastase...
Veliparib
Placebo
Whole brain rad...
18 Years - 99 YearsAbbVie
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid TumorsNCT02033551
Breast Cancer
Ovarian Cancer
Colon Cancer
Lung Cancer
Gastric Cancer
Solid Tumors
Veliparib
Carboplatin
Paclitaxel
FOLFIRI
18 Years - 99 YearsAbbVie
Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian CancerNCT02483104
Ovarian Cancer
veliparib
carboplatin
paclitaxel
20 Years - 99 YearsAbbVie
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate CancerNCT01576172
Castration-Resi...
Recurrent Prost...
Stage IV Prosta...
Abiraterone Ace...
Laboratory Biom...
Prednisone
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersNCT00588991
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Chronic Myeloid...
Chronic Myelomo...
de Novo Myelody...
Essential Throm...
Hematopoietic a...
Myelodysplastic...
Polycythemia Ve...
Recurrent Adult...
Recurrent Adult...
Secondary Myelo...
Carboplatin
Laboratory Biom...
Topotecan Hydro...
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorNCT02831179
Functional Panc...
Malignant Somat...
Merkel Cell Car...
Metastatic Adre...
Metastatic Carc...
Multiple Endocr...
Multiple Endocr...
Multiple Endocr...
Neuroendocrine ...
Non-Functional ...
Pancreatic Gluc...
Pancreatic Insu...
Recurrent Adren...
Recurrent Adren...
Recurrent Merke...
Somatostatin-Pr...
Stage III Adren...
Stage III Thyro...
Stage IIIA Merk...
Stage IIIB Merk...
Stage IV Adrena...
Stage IV Merkel...
Stage IVA Thyro...
Stage IVB Thyro...
Stage IVC Thyro...
Thymic Carcinoi...
VIP-Producing N...
Well Differenti...
Zollinger Ellis...
Capecitabine
Temozolomide
Veliparib
Pharmacological...
Laboratory Biom...
18 Years - Vanderbilt-Ingram Cancer Center
Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian CancerNCT02483104
Ovarian Cancer
veliparib
carboplatin
paclitaxel
20 Years - 99 YearsAbbVie
A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal CancerNCT01589419
Locally Advance...
veliparib
capecitabine
radiation
18 Years - 99 YearsAbbVie
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT01540565
BRCA1 Mutation ...
BRCA2 Mutation ...
Ovarian Epithel...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Laboratory Biom...
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian CancerNCT02483104
Ovarian Cancer
veliparib
carboplatin
paclitaxel
20 Years - 99 YearsAbbVie
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene VariationsNCT01827384
Advanced Malign...
Adavosertib
Carboplatin
Everolimus
Temozolomide
Trametinib
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA MutationNCT01472783
Recurrent, Epit...
Veliparib
18 Years - Vejle Hospital
A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)NCT02412371
Non-small Cell ...
Paclitaxel
Placebo for Vel...
Carboplatin
Veliparib
Radiotherapy
18 Years - AbbVie
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast CancerNCT02985658
Metastatic Brea...
Triple-Negative...
Veliparib
Cisplatin
Vinorelbine
18 Years - University of Washington
A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung CancerNCT01560104
Non-Small -Cell...
Veliparib
Carboplatin
paclitaxel
placebo
18 Years - 99 YearsAbbVie
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin LymphomaNCT00740805
Ann Arbor Stage...
Ann Arbor Stage...
Solid Neoplasm
Cyclophosphamid...
Doxorubicin Hyd...
Laboratory Biom...
Pharmacological...
Veliparib
18 Years - National Cancer Institute (NCI)
Expanded Access to VeliparibNCT03123211
Solid Tumors Wi...
Triple Negative...
High Grade Sero...
Patients Requir...
Veliparib
- AbbVie
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast CancerNCT01818063
Estrogen Recept...
HER2-negative B...
Progesterone Re...
Stage II Breast...
Stage IIIA Brea...
Stage IIIB Brea...
Stage IIIC Brea...
Triple-negative...
Paclitaxel
Carboplatin
Doxorubicin
Cyclophosphamid...
Veliparib
18 Years - Thomas Jefferson University
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal CancerNCT02305758
Untreated Metas...
Veliparib
Placebo
Modified FOLFIR...
FOLFIRI
Bevacizumab
Fluorouracil in...
18 Years - 99 YearsAbbVie
Study in Patients With SCLC of Veliparib in Combination With TopotecanNCT03227016
Small Cell Lung...
veliparib
Topotecan
18 Years - 85 YearsCentral European Society for Anticancer Drug Research
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid TumorsNCT01193140
Solid Tumor Can...
veliparib
Temozolomide
18 Years - Abbott
A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung CancerNCT01560104
Non-Small -Cell...
Veliparib
Carboplatin
paclitaxel
placebo
18 Years - 99 YearsAbbVie
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung CancerNCT01638546
Recurrent Small...
Laboratory Biom...
Placebo
Temozolomide
Veliparib
18 Years - National Cancer Institute (NCI)
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain MetastasesNCT02595905
Metastatic BRCA...
Metastatic Brea...
Metastatic Mali...
Metastatic Trip...
Recurrent Breas...
Stage IV Breast...
Cisplatin
Laboratory Biom...
Placebo Adminis...
Veliparib
18 Years - National Cancer Institute (NCI)
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerNCT01585805
Locally Advance...
Metastatic Panc...
Stage III Pancr...
Stage IV Pancre...
Biopsy
Biospecimen Col...
Cisplatin
Computed Tomogr...
Gemcitabine
Gemcitabine Hyd...
Magnetic Resona...
Veliparib
18 Years - National Cancer Institute (NCI)
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung CancerNCT01638546
Recurrent Small...
Laboratory Biom...
Placebo
Temozolomide
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine GliomasNCT01514201
Anaplastic Astr...
Brain Stem Glio...
Childhood Mixed...
Fibrillary Astr...
Giant Cell Glio...
Glioblastoma
Gliosarcoma
Untreated Child...
Untreated Child...
Untreated Child...
Untreated Child...
Untreated Child...
Untreated Child...
3-Dimensional C...
Intensity-Modul...
Laboratory Biom...
Pharmacological...
Temozolomide
Veliparib
- 21 YearsNational Cancer Institute (NCI)
Study in Patients With SCLC of Veliparib in Combination With TopotecanNCT03227016
Small Cell Lung...
veliparib
Topotecan
18 Years - 85 YearsCentral European Society for Anticancer Drug Research
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT01386385
Lung Adenocarci...
Lung Adenocarci...
Lung Large Cell...
Lung Squamous C...
Minimally Invas...
Stage III Lung ...
Stage IIIA Lung...
Stage IIIB Lung...
3-Dimensional C...
Carboplatin
Laboratory Biom...
Paclitaxel
Placebo Adminis...
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal CancerNCT01264432
Adult Solid Neo...
Peritoneal Carc...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Laboratory Biom...
Quality-of-Life...
Radiation Thera...
Veliparib
18 Years - National Cancer Institute (NCI)
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid TumorNCT01123876
Gastric Cancer
Veliparib
18 Years - 99 YearsAbbVie
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical CancerNCT01266447
Cervical Adenoc...
Cervical Adenos...
Cervical Small ...
Cervical Squamo...
Recurrent Cervi...
Stage III Cervi...
Stage IVA Cervi...
Stage IVB Cervi...
Filgrastim
Laboratory Biom...
Pegfilgrastim
Topotecan Hydro...
Veliparib
18 Years - National Cancer Institute (NCI)
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerNCT01585805
Locally Advance...
Metastatic Panc...
Stage III Pancr...
Stage IV Pancre...
Biopsy
Biospecimen Col...
Cisplatin
Computed Tomogr...
Gemcitabine
Gemcitabine Hyd...
Magnetic Resona...
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib and Temozolomide in Treating Patients With Acute LeukemiaNCT01139970
Acute Lymphobla...
Acute Myeloid L...
Acute Myeloid L...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Pro...
Adult B Acute L...
Adult B Acute L...
Adult T Acute L...
Alkylating Agen...
Chronic Myelomo...
Recurrent Adult...
Recurrent Adult...
Secondary Acute...
Laboratory Biom...
Pharmacological...
Temozolomide
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic CancerNCT01908478
Pancreatic Canc...
Veliparib
Gemcitabine
Intensity modul...
18 Years - Cedars-Sinai Medical Center
A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung CancerNCT01560104
Non-Small -Cell...
Veliparib
Carboplatin
paclitaxel
placebo
18 Years - 99 YearsAbbVie
Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair GenesNCT03061188
Advanced Solid ...
Aggressive Non-...
Recurrent Solid...
Refractory Mant...
T-Cell Non-Hodg...
Unresectable So...
Laboratory Biom...
Nivolumab
Pharmacological...
Veliparib
18 Years - Northwestern University
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal CancerNCT02305758
Untreated Metas...
Veliparib
Placebo
Modified FOLFIR...
FOLFIRI
Bevacizumab
Fluorouracil in...
18 Years - 99 YearsAbbVie
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast CancerNCT01351909
Locally Advance...
Metastatic Brea...
Recurrent Breas...
Stage IIIB Brea...
Stage IIIC Brea...
Stage IV Breast...
Cyclophosphamid...
Laboratory Biom...
Veliparib
18 Years - National Cancer Institute (NCI)
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid TumorsNCT01853306
Oncology
BRCA Mutated
High Grade Sero...
BRCA Mutated Br...
Veliparib
18 Years - 99 YearsAbbVie
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerNCT01459380
Ovarian Clear C...
Ovarian Endomet...
Ovarian Seromuc...
Ovarian Serous ...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Undifferentiate...
Bevacizumab
Carboplatin
Laboratory Biom...
Pegylated Lipos...
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine GliomasNCT01514201
Anaplastic Astr...
Brain Stem Glio...
Childhood Mixed...
Fibrillary Astr...
Giant Cell Glio...
Glioblastoma
Gliosarcoma
Untreated Child...
Untreated Child...
Untreated Child...
Untreated Child...
Untreated Child...
Untreated Child...
3-Dimensional C...
Intensity-Modul...
Laboratory Biom...
Pharmacological...
Temozolomide
Veliparib
- 21 YearsNational Cancer Institute (NCI)
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeNCT02152982
Glioblastoma
Gliosarcoma
Laboratory Biom...
Placebo Adminis...
Quality-of-Life...
Temozolomide
Veliparib
18 Years - National Cancer Institute (NCI)
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast CancerNCT01818063
Estrogen Recept...
HER2-negative B...
Progesterone Re...
Stage II Breast...
Stage IIIA Brea...
Stage IIIB Brea...
Stage IIIC Brea...
Triple-negative...
Paclitaxel
Carboplatin
Doxorubicin
Cyclophosphamid...
Veliparib
18 Years - Thomas Jefferson University
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid TumorsNCT01017640
Solid Neoplasm
Laboratory Biom...
Mitomycin
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid CancerNCT00535119
Adult Solid Neo...
BRCA1 Mutation ...
BRCA2 Mutation ...
Hereditary Brea...
Carboplatin
Laboratory Biom...
Paclitaxel
Pharmacological...
Veliparib
18 Years - National Cancer Institute (NCI)
A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung CancerNCT01560104
Non-Small -Cell...
Veliparib
Carboplatin
paclitaxel
placebo
18 Years - 99 YearsAbbVie
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical CancerNCT01281852
Cervical Adenoc...
Cervical Adenos...
Cervical Squamo...
Recurrent Cervi...
Stage IVB Cervi...
Cisplatin
Laboratory Biom...
Paclitaxel
Veliparib
18 Years - National Cancer Institute (NCI)
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerNCT01459380
Ovarian Clear C...
Ovarian Endomet...
Ovarian Seromuc...
Ovarian Serous ...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Undifferentiate...
Bevacizumab
Carboplatin
Laboratory Biom...
Pegylated Lipos...
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA StatusNCT01690598
Ovarian Cancer
Veliparib
Topotecan
18 Years - Vejle Hospital
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast CancerNCT01506609
Metastatic Brea...
Placebo
Veliparib
Carboplatin
Temozolomide
Paclitaxel
18 Years - AbbVie
ABT-888 and Temozolomide for Liver CancerNCT01205828
Hepatocellular ...
Temozolomide
ABT-888
18 Years - Georgetown University
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal CancerNCT02921256
Rectal Adenocar...
Stage II Rectal...
Stage III Recta...
Capecitabine
Fluorouracil
Intensity-Modul...
Leucovorin
Oxaliplatin
Pembrolizumab
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionNCT01366144
Breast Carcinom...
Carcinoma of Un...
Endometrial Car...
Esophageal Carc...
Liver Failure
Lung Carcinoma
Malignant Head ...
Malignant Testi...
Melanoma
Metastatic Mali...
Ovarian Carcino...
Renal Failure
Unresectable Ma...
Urothelial Carc...
Carboplatin
Laboratory Biom...
Paclitaxel
Pharmacological...
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast CancerNCT01477489
Breast Cancer
Veliparib
Standard radiat...
19 Years - University of Michigan Rogel Cancer Center
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid TumorsNCT01853306
Oncology
BRCA Mutated
High Grade Sero...
BRCA Mutated Br...
Veliparib
18 Years - 99 YearsAbbVie
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT02470585
Ovarian Cancer
Ovarian Neoplas...
Veliparib
Paclitaxel
Carboplatin
Placebo to Veli...
18 Years - AbbVie
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorNCT02831179
Functional Panc...
Malignant Somat...
Merkel Cell Car...
Metastatic Adre...
Metastatic Carc...
Multiple Endocr...
Multiple Endocr...
Multiple Endocr...
Neuroendocrine ...
Non-Functional ...
Pancreatic Gluc...
Pancreatic Insu...
Recurrent Adren...
Recurrent Adren...
Recurrent Merke...
Somatostatin-Pr...
Stage III Adren...
Stage III Thyro...
Stage IIIA Merk...
Stage IIIB Merk...
Stage IV Adrena...
Stage IV Merkel...
Stage IVA Thyro...
Stage IVB Thyro...
Stage IVC Thyro...
Thymic Carcinoi...
VIP-Producing N...
Well Differenti...
Zollinger Ellis...
Capecitabine
Temozolomide
Veliparib
Pharmacological...
Laboratory Biom...
18 Years - Vanderbilt-Ingram Cancer Center
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast CancerNCT02158507
Metastatic Trip...
Combination of ...
19 Years - University of Alabama at Birmingham
Veliparib and Temozolomide in Treating Patients With Acute LeukemiaNCT01139970
Acute Lymphobla...
Acute Myeloid L...
Acute Myeloid L...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Pro...
Adult B Acute L...
Adult B Acute L...
Adult T Acute L...
Alkylating Agen...
Chronic Myelomo...
Recurrent Adult...
Recurrent Adult...
Secondary Acute...
Laboratory Biom...
Pharmacological...
Temozolomide
Veliparib
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck CancerNCT01711541
Head and Neck S...
Stage IVA Oroph...
Stage IVB Oroph...
Carboplatin
Cisplatin
Fluorouracil
Hydroxyurea
Laboratory Biom...
Paclitaxel
Placebo Adminis...
Radiation Thera...
Veliparib
18 Years - National Cancer Institute (NCI)
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)NCT02944396
Non-Small Cell ...
pemetrexed
nivolumab
paclitaxel
veliparib
carboplatin
18 Years - AbbVie
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate CancerNCT01576172
Castration-Resi...
Recurrent Prost...
Stage IV Prosta...
Abiraterone Ace...
Laboratory Biom...
Prednisone
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib and Temozolomide in Treating Patients With Acute LeukemiaNCT01139970
Acute Lymphobla...
Acute Myeloid L...
Acute Myeloid L...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Pro...
Adult B Acute L...
Adult B Acute L...
Adult T Acute L...
Alkylating Agen...
Chronic Myelomo...
Recurrent Adult...
Recurrent Adult...
Secondary Acute...
Laboratory Biom...
Pharmacological...
Temozolomide
Veliparib
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck CancerNCT01711541
Head and Neck S...
Stage IVA Oroph...
Stage IVB Oroph...
Carboplatin
Cisplatin
Fluorouracil
Hydroxyurea
Laboratory Biom...
Paclitaxel
Placebo Adminis...
Radiation Thera...
Veliparib
18 Years - National Cancer Institute (NCI)
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 MutationsNCT03581292
Anaplastic Astr...
Glioblastoma
Malignant Gliom...
Radiation Thera...
Temozolomide
Veliparib
3 Years - 25 YearsNational Cancer Institute (NCI)
Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube CancerNCT01749397
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Floxuridine
Laboratory Biom...
Pharmacological...
Veliparib
18 Years - National Cancer Institute (NCI)
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic CancerNCT01489865
Metastatic Panc...
ABT-888 and mFO...
18 Years - Georgetown University
Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast CancerNCT01149083
Anatomic Stage ...
Anatomic Stage ...
Locally Advance...
Metastatic Brea...
Unresectable Br...
Biopsy
Biospecimen Col...
Carboplatin
Computed Tomogr...
Magnetic Resona...
Veliparib
18 Years - National Cancer Institute (NCI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: